UV Flu Technologies Commences First Shipment to Major Furniture Store
CENTERVILLE, Mass., Jan. 26, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT/UVFTD) (the "Company") is pleased to announce it has commenced shipments of its Viratech UV-400 air purifier to its first retail furniture account, the largest store of its kind in New England. The order included 20 units to be used as demos, which will be mounted on kiosks, which are now in production. The full launch is scheduled for mid-February.
"This order is a significant event for UV Flu," said Jack Lennon, President of UV Flu. "We already have a second furniture chain that has expressed interest in carrying the product, once the kiosks become available. Ultimately, the Company expects the number of stores carrying the product will continue to grow into the hundreds, as production is able to meet expected demand."
"Furniture stores typically sell thousands of mattresses per year, primarily to people who want to sleep better. There are direct links between Indoor Air Pollution and sleep-related problems. There are also direct health-related links between respiratory issues, including asthma and allergies, cardiovascular issues, cancer, and even diabetes. People are spending a significant amount of time indoors, where air quality is essential in improving health, and the quality of sleep. Customers are willing to spend thousands of dollars on entertainment centers, bedroom sets, and nurseries, so key decision-makers in the major furniture chains are starting to realize, that by adding the UV-400 to the package, the stores can dramatically improve the health and well-being of their customers, as well as the overall satisfaction with their purchase," said Mr. Lennon. "There is no other product on the market today, that is more effective in helping people sleep more soundly, while keeping them healthy while they're indoors, than the Viratech UV-400."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.
In addition, the Company's RxAir subsidiary in Dallas, TX, makes one of the worlds' finest lines of hospital-grade HEPA filtration products. The RX-3000, the Company's main product, is currently in almost 450 hospitals internationally, is FDA cleared as a Class II Medical Device, and has been shown to capture 99.99% of all airborne contaminants. The Company's product lines are in Hospitals, government buildings, casinos and restaurants around the world.
For more information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Toll-Free: 1-877-FLU-KILL, 1-877-358-5455
SOURCE UV Flu Technologies, Inc.